Huntington's disease

Clinical Neuroscience Research

Volumn 1, Issue 1-2, 2001, Pages 142-152

  Ross, Christopher A ^a   Margolis, Russell L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamine; Huntington; Movement; Neurodegeneration; Psychiatric; Trinucleotide repeat

Indexed keywords

EID: 0001337742     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(00)00014-1     Document Type: Article

References (102)

1. Harper PS. Huntington disease. London: W.B. Saunders, 1996.
2. Folstein SE. Huntington's disease: a disorder of families. Baltimore, MD: Johns Hopkins University Press, 1989.
3. Penney Jr JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: seven years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
4. Brandt J, Folstein SE, Folstein MF. Differential cognitive impairment in Alzheimer disease and Huntington's disease. Ann Neurol 1988;23:555-561.
5. Rosenblatt A, Ranen N, Nance M, Paulson J. A physician's guide to the management of Huntington's disease. 2nd ed. New York: Huntington' s Disease Society of America, 2000.
6. Hayden MR. Huntington's chorea. New York: Springer-Verlag, 1981.
7. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-247.
8. Ross CA, Margolis RL, Rosenblatt A, Ranen NG, Becher MW, Aylward E. Reviews in molecular medicine: Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine 1997;76:305-338.
9. Group HDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
10. Gusella JF, Persichetti F, MacDonald ME. The genetic defect causing Huntington's disease: repeated in other contexts? Mol Med 1997;3:238-246.
11. Ross CA. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995;15:493-496.
12. Ambrose CM, Duyao MP, Barnes G, et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994;20:27-28.
13. Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996;59:16-22.
14. McInnis MG. Anticipation - an old idea in new genes. Am J Hum Genet 1996;59:973-979.
15. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993;4:387-392.
16. Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. Correlation between the onset of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 1993;2:1547-1549.
17. Ranen NG, Stine OC, Abbott MH, et al. Anticipation and instability of (CAG)n repeats in IT-15 in parent-offspring pairs with Huntington's disease. Am J Hum Genet 1995;57:593-602.
18. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993;4:398-403.
19. Durr A, Dode C, Hahn V, et al. Diagnosis of 'sporadic' Huntington's disease. J Neurol Sci 1995;129:51-55.
20. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
21. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994;31:872-874.
22. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington disease. Ann Neurol 1996;39:132-136.
23. Ferrante RJ, Kowall NW, Beal MF, Richardson Jr EP, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985;230:561-563.
24. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato external pallidal projection neurons in presymptomatic Huntington' s disease. Ann Neurol 1992;31:425-430.
25. Kowall NW, Ferrante RJ, Martin JB. Patterns of cell loss in Huntington's disease. Trends Neurosci 1987;10:24-29.
26. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington' s disease. J Neuropathol Exp Neurol 1985;44:559-577.
27. Myers RH, Vonsattel J-P, Stevens TJ, et al. Clinical and neuropathologic assessment of severity in Huntington disease. Neurology 1988;38:341-347.
28. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133:257-261.
29. Graveland GA, Williams RS, DiFiglia M. A Golgi study of the human neostriatum: neurons and afferent fibers. J Comp Neurol 1985;234:317-333.
30. Sotrel A, Williams RS, Kaufmann WE, Myers RH. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington' s disease: a quantitative Golgi study. Neurology 1993;43:2088-2986.
31. Folstein SE, Phillips III JA, Meyers DA, et al. Huntington's disease: two families with differing clinical features show linkage to the G8 probe. Science 1985;229:776-779.
32. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuntes in brain. Science 1997;277:1990-1993.
33. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998;4:387-397.
34. Ross CA, Margolis RL, Becher MW, Wood JD, Engelender S, Sharp AH. Pathogenesis of polyglutamine neurodegenerative diseases: towards a unifying mechanism. In: Wells RD, Warren ST, editors. Genetic instabilities and hereditary neurological diseases, San Diego, CA: Academic Press, 1998.
35. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions (Nil) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
36. Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington's disease. Nature 1987;326:194-197.
37. Kaufmann WE, Reiss AL. Molecular and cellular genetics of fragile X syndrome. Am J Med Genet 1999;88:11-24.
38. White JK, Auerbach W, Duyao MP, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington' s disease CAG expansion. Nat Genet 1997;17:404-410.
39. Beal MF, Kowall NW, Ellison DZW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171.
40. Beal MF, Brouillet E, Jenkins B, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
41. Grunewald T, Beal MF. Bioenergetics in Huntington's disease. Ann N Y Acad Sci 1999;893:203-213.
42. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998;18:667-682.
43. Utz PJ, Anderson P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ 2000;7:589-602.
44. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders: part 2: control of cell death. Arch Neurol 2000;57:801-804.
45. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
46. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646-653.
47. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39:385-389.
48. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of the Huntington's disease gene (IT15) protein product. Neuron 1995;14:1065-1074.
49. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-1081.
50. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995;378:403-406.
51. Velier J, Schwarz C, Young C, et al. Wild-type and mutant huntingtin localize to the golgi complex and to vesicles in the peripheral cytoplasm in fibroblasts of control and HD patients. Soc Neurosci Abstracts 1996;22:226.
52. Gusella JF, MacDonald ME. Huntingtin: a single bait hooks many species. Curr Opin Neurobiol 1998;8:425-430.
53. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996;347:350.
54. Boutell JM, Thomas P, Neal JW, et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999;8:1647-1655.
55. Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 1993;74:955-956.
56. Margolis RL, Abraham MA, Gatchell SB, et al. cDNAs with long CAG trinucleotide repeats from human brain. Hum Genet 1997;100:114-122.
57. Perutz M. Polar zippers: their role in human disease. Protein science, 3rd ed. London: Cambridge University Press, 1994. pp. 1629-1637.
58. Kahlem P, Terre C, Green H, Djian P. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc Natl Acad Sci USA 1996;93:14580-14585.
59. Georgalis Y, Starikov EB, Hollenbach B, et al. Huntingtin aggregation monitored by dynamic light scattering. Proc Natl Acad Sci USA 1998;95:6118-6121.
60. Scherzinger E, Sittler A, Schweiger K, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington' s disease pathology. Proc Natl Acad Sci USA 1999;96:4604-4609.
61. Peters MF, Nucifora Jr FC, Kushi J, et al. Nuclear targeting of mutant huntingtin increases toxicity. Mol Cell Neurosci 1999;14:121-128.
62. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998;7:1355-1361.
63. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55-66.
64. Moulder KL, Onodera O, Burke JR, Strittmatter WJ, Johnson Jr EM. Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length. J Neurosci 1999;19:705-715.
65. Hackam AS, Singaraja R, Wellington CL, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998;141:1097-1105.
66. Martindale D, Hackam A, Wieczorek A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998;18:150-154.
67. Cooper JK, Schilling G, Peters MF, et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 1998;7:783-790.
68. Kim M, Lee HS, LaForet G, et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999;19:964-973.
69. Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 1999;8:1227-1236.
70. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998;273:9158-9167.
71. Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin Genet 2000;57:1-10.
72. Wellington CL, Singaraja R, Ellerby L, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J Biol Chem 2000;275:19831-19838.
73. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999;22:623-633.
74. Ellerby LM, Andrusiak RL, Wellington CL, et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999;274:8730-8736.
75. Mangiarini L, Sathasivam S, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
76. Carter RJ, Lione LA, Humby T, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999;19:3248-3257.
77. Murphy KP, Carter RJ, Lione LA, et al. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 2000;20:5115-5123.
78. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999;8:397-407.
79. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998;20:198-202.
80. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181-192.
81. Wheeler VC, White JK, Gutekunst CA, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000;9:503-513.
82. Li SH, Li H, Torre ER, Li XJ. Expression of Huntingtin-associated protein-1 in neuronal cells implicates a role in neuritic growth. Mol Cell Neurosci 2000;16:168-183.
83. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
84. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998;93:939-949.
85. Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998;21:633-642.
86. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000;287:1837-1840.
87. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999;23:425-428.
88. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 1999;96:179-184.
89. Satyal SH, Schmidt E, Kitagawa K, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci USA 2000;97:5750-5755.
90. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
91. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996;11:273-277.
92. Feigin A, Keiburtz K, Como P, et al. Assessment of Coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996;11:321-323.
93. Ranen NG, Peyser CE, Coyle J, et al. A controlled trial of idebenone in Huntington's disease. Mov Disord 1996;11:549-554.
94. Peyser CE, Folstein MF, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry 1995;152:1771-1775.
95. Heiser V, Scherzinger E, Boeddrich A, et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci USA 2000;97:6739-6744.
96. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 2000;97:7841-7846.
97. Ona VO, Li M, Vonsattel JP, Andrews LJ, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999;399:263-267.
98. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
99. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
100. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ. Delaying the onset of Huntington's in mice. Nature 2000;404:721-722.
101. Ross CA, Hayden MR. Huntington's disease. In: Rubinsztein DC, Hayden MR, editors. Analysis of triplet repeat disorders: Bios, 1998. pp. 169-208.
102. Ross CA, Margolis RL. Huntington's disease, In Neuropsychopharmacology: a fifth generation of progress. Ed. Davies, editor. (2000) in press.